InnovAge Holding Corp (NASDAQ: INNV) reported fourth-quarter and full fiscal-year 2026 results on 8 September 2026, alongside fiscal 2027 guidance of $1.05bn to $1.085bn in revenue.
Shares closed 13.12% higher at $11.90 the following session, on volume 1.91 times the 20-day average, according to consolidated exchange data.
Guidance beats, but the EBITDA number needs context
Management told investors adjusted EBITDA rose 175% in fiscal 2026, framing the increase around a long-term margin target of 10%. The company said net income was hit by one-time legal accruals during the year.
That 175% figure is a non-GAAP measure calculated by the company; it does not correspond to any GAAP figure in InnovAge’s public filings. The most recent GAAP net income on file, for the quarter ended 31 March 2026, was a loss of $29.461m, with diluted earnings per share of -$0.22. Quarterly revenue over the same run of filings climbed from $188.898m in the quarter to December 2023 to $251.943m in the quarter to March 2026, the last figure reported before Tuesday’s release.
InnovAge’s fiscal year runs to 30 June, making a September release for the fourth quarter consistent with the company’s established reporting calendar; it followed the same cadence a year earlier when it announced results for the period ended 30 June 2025.
Fiscal 2027 targets
For fiscal 2027, InnovAge guided to a census of 8,625 to 8,850 participants, revenue of $1.05bn to $1.085bn, and adjusted EBITDA of $105m to $115m. Management framed the targets around preserving margins in what it called a more challenging rate environment, language that lands against a backdrop of a 10-year Treasury yield at 4.78% in early September, still elevated by recent historical standards.
The company also described a shift into what it calls ‘InnovAge Holding 3.0’, centred on scaling operations, expanding value-based care, investing in artificial intelligence and clinical technology, and exploring new markets and acquisitions.
Sponsor filings land in the same two-minute window
Three private-equity sponsors linked to InnovAge’s ownership structure each filed a Form 4 with the SEC in the two minutes surrounding the earnings release on 8 September: TCO Group Holdings, L.P. at 22:00:09 UTC, Apax X (Guernsey) USD AIV LP at 22:00:07 UTC, and WCAS XII Associates LLC at 22:00:05 UTC.
None of the three filings discloses whether the entities were adding to or reducing their positions. The timing places all three trades within seconds of the results going public, on a day the stock ultimately jumped 13% and short-sale volume, tracked by FINRA, rose to a ratio of 0.66, up from 0.374 a week earlier on 1 September.
Whether that short-volume increase reflects hedging, market-making activity, or directional bets, the data does not say. What is clear is that the filing timestamps and the earnings release landed within the same window, giving traders scrutinising the print an added data point to weigh alongside the headline guidance figures.
What the numbers show over time
InnovAge’s GAAP results have been volatile across recent quarters. Net income swung from a loss of $13.221m in the quarter to December 2024 to a profit of $10.618m in the quarter to December 2025, before reverting to a $29.461m loss in the quarter to March 2026. Diluted EPS across the same stretch moved from -$0.10 to $0.08 and back to -$0.22, underlining how sensitive the bottom line has been to one-off items, including the legal accruals management flagged on Tuesday’s call.
Revenue growth has been steadier. The top line rose in each of the eight quarters disclosed in InnovAge’s 10-Q filings, from $188.898m in the December 2023 quarter to $251.943m in the March 2026 quarter, a run of sequential increases that underpins the case for the higher fiscal 2027 revenue guidance now on the table.
Investors will get the first full test of that guidance when InnovAge reports its fiscal 2027 first-quarter results, expected in line with the company’s established September-to-November reporting rhythm.
This article is for information only and is not investment advice or a recommendation to buy or sell any asset. Markets move quickly; figures are correct as sourced at the time of writing. Always do your own research before making financial decisions.
